Amber Therapeutics offers a dry‑powder inhalation (DPI) platform that generates 1–3 µm particles for deep lung deposition and delivers consistent doses across 30–90 L/min inspiratory flows. The formulation‑agnostic system supports small‑molecule, peptide, and nucleic‑acid therapeutics and includes a breath‑actuated inhaler with real‑time dose counter and flow sensor, enabling pharmaceutical developers to improve efficacy and adherence for respiratory diseases such as asthma and COPD.
Funding
$101.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with asthma, COPD, and other chronic respiratory diseases often receive suboptimal drug delivery due to inefficient aerosol generation, variable lung deposition, and complex inhaler techniques, leading to reduced therapeutic efficacy and increased systemic side effects.
Solution
Amber Therapeutics addresses these gaps with a proprietary dry‑powder inhalation (DPI) platform that generates highly respirable particles optimized for deep lung penetration. The technology leverages engineered particle morphology and controlled aerodynamic diameter to achieve consistent dose emission across a wide range of inspiratory flow rates, reducing reliance on patient technique. By delivering medication directly to the target site, the platform maximizes local drug concentration while minimizing systemic exposure, which can improve clinical outcomes and patient adherence. The DPI system is designed for integration with a broad portfolio of small‑molecule and biologic candidates, enabling rapid formulation development and scalable manufacturing for both early‑stage and late‑stage respiratory therapeutics.
Target Audience
The primary customers are pharmaceutical developers and biotech firms seeking an advanced inhalation delivery system for respiratory indications, as well as clinicians and healthcare providers treating asthma, COPD, and related lung diseases.
Features
- Engineered micronized particles with narrow aerodynamic size distribution (1–3 µm) for high alveolar deposition
- Breath‑actuated, low‑resistance inhaler design that delivers consistent dose across 30–90 L/min inspiratory flows
- Formulation‑agnostic platform supporting small molecules, peptides, and nucleic‑acid therapeutics
- Integrated moisture‑control packaging to preserve powder stability and extend shelf life
- Scalable spray‑dry and jet‑mill manufacturing processes compatible with GMP facilities
- Real‑time dose‑counter and inhalation flow sensor for patient feedback and adherence monitoring
- Compatibility with existing clinical trial inhalation protocols and regulatory pathways